prediction
This widens Foundayo's commercial lane beyond weight loss alone.
A prediction by MY READ. Statements are as reported by the cited publishers — not verified by DecisionGateway.
This widens Foundayo's commercial lane beyond weight loss alone.
Discussion
Related claims
Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.Eli Lilly · statementWhat changes this read: regulators reject the weight-loss-independent analysis, safety or adherence weakens in full publication, or payers restrict coverage despite an approval.MY READ · predictionLilly's analysis attributed 39.6% of the treatment effect to factors beyond weight loss.Lilly · statementAt 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.Lilly · statementThe FDA requires a warning about a risk of sudden blindness with popular weight-loss drugs.noticias_telemundo · statementVodafone raised its profit forecast after a cost cutting campaign.theedgesg · statement